← All Connect Biopharma Holdings LTD filings

Connect Biopharma Holdings LTD 10-Q quarterly reports

Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.

NASDAQ
CNTB
Connect Biopharma Holdings LTD
10-Q: Connect Biopharma Q1 2026: Increased R&D Spend, Private Placement Boosts Cash
Connect Biopharma Holdings Limited reported a net loss of $19.4 million for Q1 2026, with a significant increase in R&D expenses, offset by proceeds from a private placement that bolstered cash reserves.
NASDAQ
CNTB
Connect Biopharma Holdings LTD
10-Q: Connect Biopharma Reports Increased Losses, Advances Rademikibart
Connect Biopharma reported a significant increase in net loss and cash burn for the nine months ended September 30, 2025, while advancing its lead drug candidate, rademikibart, into Phase 2 studies for asthma and COPD.
NASDAQ
CNTB
Connect Biopharma Holdings LTD
10-Q: Connect Biopharma Reports Q2 Loss Amid R&D Boost
Connect Biopharma reported a significant net loss in Q2 2025 as research and development expenses increased, while advancing its lead asset rademikibart with positive clinical data and an NDA submission in China.
NASDAQ
CNTB
Connect Biopharma Holdings LTD
10-Q: Connect Biopharma Reports Q1 2025 Financial Results and Provides Business Update
Connect Biopharma, a clinical-stage biopharmaceutical company, announced its financial results for the first quarter of 2025, highlighting progress in its rademikibart program and providing updates on recent developments.